scholarly journals Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

2020 ◽  
Vol 10 (10) ◽  
pp. 1528-1543 ◽  
Author(s):  
Timothy A. Yap ◽  
Rebecca Kristeleit ◽  
Vasiliki Michalarea ◽  
Stephen J. Pettitt ◽  
Joline S.J. Lim ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Parp Inhibitor ◽  
Akt Inhibitor

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

2015 ◽  
Vol 33 (3) ◽  
pp. 710-719 ◽  
Author(s):  
Analia Azaro ◽  
Jordi Rodon ◽  
Antonio Calles ◽  
Irene Braña ◽  
Manuel Hidalgo ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Metastatic Cancer ◽  
Akt Inhibitor ◽  
S6 Kinase ◽  
P70 S6 Kinase

Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3000-3000 ◽  
Author(s):  
A. R. Tan ◽  
D. Gibbon ◽  
M. N. Stein ◽  
R. A. Moss ◽  
V. Karantza ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Parp Inhibitor ◽  
Preliminary Results

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 2500-2500 ◽  
Author(s):  
Udai Banerji ◽  
Emma Jane Dean ◽  
Jose Alejandro Perez-Fidalgo ◽  
Gerald Batist ◽  
Philippe L. Bedard ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Gynecological Cancers ◽  
Akt Inhibitor
Sign in / Sign up

Export Citation Format

Share Document